tbuckley/cabot-search huggingface dataset:
Breast Cancer Screening in Denmark
Authors: Changjun Wang, Yidong Zhou, Feng Mao, Yan Lin, Qiang Sun
Journal: Annals of Internal Medicine (2017)

Letters3 October 2017Breast Cancer Screening in DenmarkChangjun Wang, MD, Yidong Zhou, MD, Feng Mao, MD, Yan Lin, MD, and Qiang Sun, MDChangjun Wang, MDFrom Peking Union Medical College Hospital, Beijing, China.Search for more papers by this author, Yidong Zhou, MDFrom Peking Union Medical College Hospital, Beijing, China.Search for more papers by this author, Feng Mao, MDFrom Peking Union Medical College Hospital, Beijing, China.Search for more papers by this author, Yan Lin, MDFrom Peking Union Medical College Hospital, Beijing, China.Search for more papers by this author, and Qiang Sun, MDFrom Peking Union Medical College Hospital, Beijing, China.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0268 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Jørgensen and colleagues' study (1) concluded that mammography screening was not associated with a lower incidence of advanced tumors but increased the incidence of nonadvanced cancer with an incidence rate ratio (IRR) of 1.49 (95% CI, 1.43 to 1.54). However, the methods used to calculate the IRR may undermine the strength of this study. The authors calculated the IRR by using the incidence rate after screening as a numerator and before screening as a denominator. We believe that—similar to hazard ratios, which are widely used for survival analysis—a more appropriate definition of IRR would be the ratio ...Reference1. Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl PH. Breast cancer screening in Denmark: a cohort study of tumor size and overdiagnosis. Ann Intern Med. 2017;166:313-23. [PMID: 28114661]. doi:10.7326/M16-0270 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Peking Union Medical College Hospital, Beijing, China.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0268. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoBreast Cancer Screening in Denmark Karsten Juhl Jørgensen , Peter C. Gøtzsche , Mette Kalager , and Per-Henrik Zahl Breast Cancer Screening in Denmark Sameer Bhargava , Kaitlyn Tsuruda , and Solveig Hofvind Breast Cancer Screening in Denmark Karsten Juhl Jørgensen , Peter C. Gøtzsche , Mette Kalager , and Per-Henrik Zahl Breast Cancer Screening in Denmark Tony H.H. Chen and Stephen W. Duffy Metrics 3 October 2017Volume 167, Issue 7Page: 522KeywordsBreast cancerBreast cancer screeningCancer screeningDisclosureForecastingHazard ratioMammographyMortality ePublished: 3 October 2017 Issue Published: 3 October 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
HIV bio-behavioural survey among men who have sex with men in Barcelona, Bratislava, Bucharest, Ljubljana, Prague and Verona, 2008-2009
Authors: M Mirandola, C Folch Toda, I Krampac, I Nita, D Stanekova, D Stehlikova, I Toskin, L Gios, J P Foschia, M Breveglieri, M Furegato, E Castellani, M G Bonavina, None the SIALON network
Journal: Eurosurveillance (2009)

Data from 23 European countries show that the annual number of HIV diagnoses in men who have sex with men (MSM) increased by 86% between 2000 and 2006. This paper reports the main preliminary results of a bio-behavioural survey in MSM with a specific focus on HIV prevalence and use of United Nations General Assembly Special Session (UNGASS) indicators in six cities in Southern and Eastern Europe. Time-location sampling (TLS) was used. A total number of 2,356 questionnaires and 2,241 oral fluid samples were collected (invalid samples 4.1%). The data show different socio-demographic patterns across countries regarding age, level of education, living conditions, living area and self-identity. Southern European cities had the highest percentage of people who had tested for HIV and collected the result. More than 50% of respondents in the sample from Barcelona reported having used a condom last time they had anal sex (57.2%), whilst in all other cities this proportion was below 50%. The cities with the highest HIV prevalence in MSM were Barcelona (17.0%) and Verona (11.8%) whilst lower percentages were reported in Bratislava (6.1%), Bucharest (4.6%), Ljubljana (5.1%) and Prague (2.6%). The low prevalence in Eastern European cities is encouraging. However, with the level of high-risk sexual behaviour documented and the lower frequency of HIV test seeking behaviour, there is a clear risk of an increase in HIV transmission.
Characterisation of asthma subgroups associated with circulating YKL-40 levels
Authors: Jose L. Gomez, Xiting Yan, Carole T. Holm, Nicole Grant, Qing Liu, Lauren Cohn, Vera Nezgovorova, Deborah A. Meyers, Eugene R. Bleecker, Gina M. Crisafi, Nizar N. Jarjour, Linda Rogers, Joan Reibman, Geoffrey L. Chupp
Journal: European Respiratory Journal (2017)

The chitinase-like protein YKL-40 mediates airway inflammation and serum levels are associated with asthma severity. However, asthma phenotypes associated with YKL-40 levels have not been precisely defined. We conducted an unsupervised cluster analysis of asthma patients treated at the Yale Center for Asthma and Airways Disease (n=156) to identify subgroups according to YKL-40 level. The resulting YKL-40 clusters were cross-validated in cohorts from the Severe Asthma Research Programme (n=167) and the New York University/Bellevue Asthma Repository (n=341). A sputum transcriptome analysis revealed molecular pathways associated with YKL-40 subgroups. Four YKL-40 clusters (C1–C4) were identified. C3 and C4 had high serum YKL-40 levels compared with C1 and C2. C3 was associated with earlier onset and longer duration of disease, severe airflow obstruction, and near-fatal asthma exacerbations. C4 had the highest serum YKL-40 levels, adult onset and less airflow obstruction, but frequent exacerbations. An airway transcriptome analysis in C3 and C4 showed activation of non-type 2 inflammatory pathways. Elevated serum YKL-40 levels were associated with two distinct clinical asthma phenotypes: one with irreversible airway obstruction and another with severe exacerbations. The YKL-40 clusters are potentially useful for identification of individuals with severe or exacerbation-prone asthma.
Reassurance for many healthy women considering HRT
Authors: Chrisandra Shufelt, C Noel Bairey Merz
Journal: BMJ (2017)

But individual assessment of risk benefit balance remains essential 

Many women remain fearful of using menopause hormone therapy because of concerns about the risk of heart attack, stroke, and breast cancer. These concerns were prompted by the two Women’s Health Initiative (WHI) clinical trials that were stopped early in 2002 and 2004. In the first trial women who took conjugated equine oestrogen and medroxyprogesterone had an increased incidence of heart attacks, strokes, and breast cancer compared with those taking placebo.1 The second trial in women with a hysterectomy found an increased incidence of stroke and venous thromboembolism in those treated with conjugated equine oestrogen compared with the placebo group but no increased risk of breast cancer.2 Neither trial reported an increase in total mortality among actively treated women compared with placebo (hazard ratio 0.98 (95% confidence interval 0.82 to 1.18) for the oestrogen plus progestin trial and 1.04 (0.88 to 1.22) for the oestrogen trial).12

The results sent shock waves through affected patient and healthcare communities. Prescriptions for hormone therapy, …
P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).
Authors: Shalini Subramaniam, Guy C. Toner, Martin R. Stockler, Andrew James Martin, Farzana D. Pashankar, A. Lindsay Frazier, Danish Mazhar, Kate Ford, Euan Thomas Walpole, Amanda Gwendolyn Stevanovic, David Wyld, Simon Troon, Fritha J. Hanning, Alison Jane Birtle, Matthew James Wheater, Robert A. Huddart, Jeff D. White, Sheri L. Spunt, Peter S. Grimison
Journal: Journal of Clinical Oncology (2020)

TPS425 Background: Bleomycin, etoposide, cisplatin (BEP) given 3-weekly x 4 remains standard 1st line chemotherapy for metastatic GCTs. Acceleration of standard regimen with shorter cycle lengths has improved cure rates in other cancers. This is the first international randomised clinical trial for intermediate and poor-risk metastatic extracranial GCTs involving both adult and paediatric age group males and females. We aim to determine if accelerated BEP is superior to standard BEP. Methods: DESIGN: Open label, randomised, stratified multicentre, 2 stage, phase 3 trial. Primary endpoint for stage I (n = 150) is the achievement of a favourable response, and for entire trial (n = 500) is progression free survival (PFS). SAMPLE SIZE: 150 and 500 patients gives &gt; 80% power to detect a 20% improvement in the favourable response rate and 7% absolute improvement in 2yr PFS, respectively. POPULATION: Males and females aged 11-45 years with intermediate or poor-risk metastatic GCTs of the testis, ovary, retroperitoneum or mediastinum for 1st line chemotherapy. TREATMENT: Randomisation 1:1 to 4 cycles of “standard BEP” or “accelerated BEP”: cisplatin 20mg/m 2 IV D1-5; etoposide 100mg/m 2 IV D1-5; bleomycin 30000 IU IV weekly; and pegylated G-CSF SC D6 or filgrastim daily; given every 3 weeks or every 2 weeks respectively. Accelerated BEP arm receives 4 additional weekly doses of bleomycin. ASSESSMENTS: Response assessments at 30 day safety assessment, and 6 months from randomisation or after all post-chemotherapy intervention is completed. Regular follow-up up to 5 years, then annually. Archival tumour tissue and baseline blood collected for translational substudies. STATUS: 25 sites open in ANZ, 13 sites open in UK (led by Cambridge Clinical Trials Unit), 67 sites open in the USA (led by Children’s Oncology Group). As of September 2019, 98 patients have been recruited triggering the first formal interim analysis. Clinical trial information: NCT02582697.
Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC).
Authors: Johanna C. Bendell, Tamara Sauri, Antonio Cubillo, Carlos López-López, Pilar Garcia Alfonso, Maen A. Hussein, M. Luisa Limon, Andres Cervantes, Clara Montagut, Cristina Santos, Alberto Bessudo, Manuel R. Modiano, Veerle Moons, Johannes Andel, Jaafar Bennouna, Andre Van Der Westhuizen, Leslie M. Samuel, Oliver Krieter, Simona Rossomanno, Herbert Hurwitz
Journal: Journal of Clinical Oncology (2017)

3539 Background: VEGF-A and ANG-2 have complementary roles in regulation of tumor angiogenesis. Targeting VEGF-A with BEV in combination chemotherapy (CT) in mCRC has proven to increase PFS and OS. ANG-2 is overexpressed and associated with poor outcome of mCRC pts receiving BEVcontaining treatment. Hence, dual blockade of VEGF-A and ANG-2 by the bispecific mAb VAN with standard CT may improve clinical activity in mCRC. Methods: All pts received mFOLFOX-6 and were randomized 1:1 to also receive intravenous VAN 2000 mg every other week (Q2W) (Arm A) or BEV 5 mg/kg Q2W (Arm B). The primary end point was investigator assessed progression-free survival (PFS). Key eligibility criteria included pts with non-resectable mCRC, no prior therapy for advanced disease, PS 0-1, adequate organ functions, and no history of GI fistula/perforation or intraabdominal abscess within the last 6 months. Results: 192 pts were randomized (Arms A/B, n = 95/97) by 39 sites in 7 countries, between Oct 2014 and May 2016. Median follow-up was 17.6 months (range 2.8 – 20.7). In the ITT population (n = 189; Arms A/B, n = 94/95), median PFS in Arms A and B was 11.3 and 11.0 months (stratified hazard ratio (HR) 1.00 (95%CI 0.64-1.58; p = 0.985)), respectively. Objective response rate was 52.1% vs 57.9%. Relevant prognostic factors incl. RAS/BRAF status and tumor sidedness were balanced between arms and did not significantly influence outcome. Baseline plasma ANG-2 levels were prognostic in both arms but not predictive for response to VAN. The overall incidence of adverse events (AEs) grade ≥ 3 was similar (Arms A/B, 83.9%/82.1%); AEs grade ≥ 3 attributed to the mode of action of VAN/BEV included hypertension (37.6%/18.9%), hemorrhage (2.2%/1.1%), thromboembolic events (venous 6.5%/2.1%; arterial 1.1%/3.2%) and GI perforations incl. GI fistula &amp; abdominal abscess (10.6%/8.4%). Conclusions: The combination of VAN and FOLFOX did not improve PFS and was associated with a marked increase in hypertension compared with BEV plus FOLFOX. Our results strongly suggest that ANG-2 is not a relevant therapeutic target in the setting of first line mCRC. Clinical trial information: NCT02141295.
Pathological evaluation of tumor infiltrating lymphocytes and the benefit of nivolumab in advanced non-small cell lung cancer (NSCLC)
Authors: I. Gataa, L. Mezquita, E. Auclin, S. Le Moulec, P. Alemany, M. Kossai, J. Massé, C. CARAMELLA, J. Remon Masip, J. Lahmar, R. Ferrara, A. Gazzah, J-C. Soria, D. Planchard, B. Besse, J. Adam
Journal: Annals of Oncology (2017)
Personalized and rapid food allergy test using natural allergenic extracts
Authors: M. Frossard, N. Gasilova, L. Arlettaz, E. Dayer, H. H. Girault
Journal: Allergy (2017)

Reference EPFL-CONF-231675Afficher la publication dans Web of Science Notice creee le 2017-10-09, modifiee le 2017-10-14
Stewart-Treves Syndrome on the Lower Extremity Associated to Idiopathic Chronic Lymphedema Visualized on FDG PET/CT
Authors: Jane Maestri Brittain, Tine Nymark, Malene Grubbe Hildebrandt, Dorrit Hovgaard, Kim Francis Andersen
Journal: Clinical Nuclear Medicine (2017)

Abstract Angiosarcomas are highly malignant and rare tumors of vascular or lymphatic endothelial cell origin with a poor prognosis. Lymphangiosarcoma associated with chronic lymphedema is known as Stewart-Treves syndrome. Stewart-Treves syndrome is primarily described in patients with lymphedema of an upper extremity occurring after breast cancer surgery including radical axillary lymph node dissection and subsequent radiotherapy. It is rarely described in the presence of idiopathic chronic lymphedema of the lower extremities. We present a case of lymphangiosarcoma visualized on 18 F-FDG PET/CT, where Stewart-Treves syndrome is secondary to probably a combination of idiopathic chronic lymphedema of the lower extremities and systemic immunosuppressive treatment.
Disseminação de uma epidemia de estafilococos aureus resistentes à meticilina nos hospitais alemães
Authors: W Witte, C Cuny, C Braulke, D Heuck, I Klare
Journal: Eurosurveillance (1997)

As estirpes de Staphylococcus aureus resistentes a multiplos antibioticos, incluindo os que sao resistentes a meticilina (MRSA), representam um problema major no controlo das infeccoes adquiridas no hospital. Algumas estirpes mostram uma capacidade de se propagarem desde que se introduzam no hospital. Diferentes estirpes de MRSA (EMRSA) identificadas pelo seu fenotipo tem-se propagado de uma regiao a outra nos hospitais britânicos (1). Estudos multicentricos conduzidos pela Paul Ehrlich Society for Chemotherapy tem mostrado que a frequencia de MRSA entre as infeccoes por S. aureus adquiridas nos hospitais da Alemanha aumentou de 1,7% para 8,7% entre 1990 e 1995 (2,3).
Abstract 12915: The Contribution of Transient Receptor Potential Vanilloid 4 (TRPV4) to Endothelium-Dependent Dilation is Enhanced by Shear Stress
Authors: Owen L Woodman, William G Darby, Simon Potocnik, Peter McIntyre
Journal: Circulation (2016)

Shear stress on the endothelial surface of blood vessels influences vasodilator mechanisms. We tested the hypothesis that shear enhances the contribution of TRPV4 ion channels to vasodilation and investigated whether there was a functional interaction with the muscarinic receptor 3 (MR3). In HEK293 cells we established that the MR3 signals to and opens TRPV4. Using pressure myography, dilator responses to the TRPV4 agonist GSK1016790A and to the MR3 agonist acetylcholine (ACh) were examined in rat cremaster arterioles which had either experienced no shear stress or within 15 min of exposure to high shear stress (200 μl/min flow, 6 min, n=8-12). In control vessels GSK1016709A caused vasodilation (pEC 50 7.85 ± 0.15 M, R max 109 ± 6 %) which was attenuated by the TRPV4 antagonist GSK2193874 (100 nM) (pEC 50 6.26 ± 0.14 M, p&lt;0.05, R max 84 ± 5 %) and abolished by endothelium denudation. When responses were assessed in shear treated arterioles there was an increase in sensitivity to GSK1016790A (pEC 50 8.39 ± 0.11, p&lt;0.05, R max 107 ± 3 %). Vasodilation to ACh (pEC 50 7.23 ± 0.06 M, R max 99 ± 1 %) was not affected by exposure to shear forces (pEC 50 6.94 ± 0.08 M, R max 98 ± 1 %). Dilator responses to ACh were not affected by the TRPV4 antagonist in control arterioles (pEC 50 7.24 ± 0.07 M, R max 102 ± 2 %) but, in shear treated vessels, the ACh response was attenuated by GSK2193874 (pEC 50 6.26 ± 0.12 M, p&lt;0.05, R max 95 ± 3 %) indicating that shear forces stimulate a functional interaction between TRPV4 and MR3. TRPV4 antibody immunofluorescence measured in the arterioles indicated localisation of ion channels to the endothelium, but the induction of shear stress on the endothelium had no effect on the localisation of TRPV4 within endothelial cells of the intact arterioles. Expression of TRPV4 channels at the cell surface was not affected by shear forces as immunofluorescence of an antibody for the extracellular TRPV4 domain was similar in both groups of arterioles. Shear stress increases the sensitivity of endothelial TRPV4 ion channels to a selective agonist and reveals their contribution to muscarinic receptor mediated endothelium-dependent vasodilation. Investigating dilator responses in isolated arterioles without exposure to shear forces may under estimate the contribution of TRPV4.
Detección de un brote de tos ferina mediante vigilancia activa en Chipre en 2003
Authors: M Theodoridou, A Hadjipanagis, N Persianis, S Makri, C Hadjichristodoulou
Journal: Eurosurveillance (2007)

La tos ferina es una enfermedad de gran importancia para la salud publica que sigue careciendo de un sistema de vigilancia eficiente. Es una enfermedad de declaracion obligatoria en Chipre desde 1930, y su incidencia ha sido de 1 por 100.000 personas en los ultimos 10 anos.
A phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Kα-selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy
Authors: T.K. Choueiri, C. Porta, C. Suarez Rodriguez, R. Alter, P. Czaykowski, I. Duran, M. Gross-Goupil, E. Kalinka-Warzocha, B. Melichar, C. Patel, R. Neuwirth, A. Enke, F. Zohren, T. Powles
Journal: Annals of Oncology (2017)
Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia.
Authors: Guillermo Montalban-Bravo, Prithviraj Bose, Yesid Alvarado, Naval Guastad Daver, Farhad Ravandi, Gautam Borthakur, Koichi Takahashi, Michael Andreeff, Jorge E. Cortes, Courtney Denton Dinardo, Elias Jabbour, Tapan M. Kadia, Steven Kornblau, Maro Ohanian, Xuelin Huang, Graciela M. Nogueras-Gonzalez, Kristy Bodden, Sherry Pierce, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Journal of Clinical Oncology (2017)

7020 Background: Improving the current response and survival outcomes of patients with higher risk MDS and CMML is fundamental. Guadecitabine is a next generation hypomethylating agent with increased length of exposure compared to decitabine and clinical activity in patients with MDS. Methods: Single arm phase 2 clinical trial of guadecitabine at a dose of 60mg/m 2 sc daily for 5 days (days 1-5) every 28 days for patients with newly diagnosed MDS or CMML classified as Intermediate-2 or High risk by IPSS. Primary endpoint is complete response (CR). Responses were evaluated following the revised 2006 International Working Group criteria. Sequencing data was obtained at the time of pre-treatment evaluation by the use of a 28-gene next generation sequencing platform. Study included stopping rules for response and toxicity. Overall survival (OS) was censored at the time of transplant. Results: A total of 53 patients have been enrolled: 50 (94%) are evaluable for toxicity and 44 (83%) for response. Median age is 67 years (49-87). A total of 43 (86%) patients have MDS and 7 (14%) have CMML. A total of 21 (42%) have complex karyotype. Sequencing data was available in 48 (96%) patients with TP53 mutations being the most frequently detected in 36% patients. After a median of 6 treatment cycles (1-20), the ORR is 71% including 32% CR. Median best response occurred by 3 cycles (1-6). Seven (21%) out of 33 evaluable patients achieved a complete cytogenetic response. Ten (20%) subjects proceed to allogeneic stem cell transplantation. Median follow up was 6.3 months (0-23). Median OS is 14.1 months (CI 13.3-14.9 months) and median EFS is 8.4 months (CI 5.6-11.2 months). Forty-five (90%) patients experienced at least one AE during therapy. Most common grade 1-2 AEs included fatigue (66%), nausea (38%) and dyspnea (26%). Dose reductions due to cytopenias were required in 17 (34%) patients. Early 8-week mortality occurred in 3 (6%) patients. Conclusions: Guadecitabine is well-tolerated and active in patients with higher-risk MDS and CMML even in the presence of adverse biological features such as high frequency of complex karyotype, therapy related disease and TP53 mutations. Clinical trial information: NCT02131597.
<i>Black Women in Medicine</i>—A Documentary
Authors: Kimberly D. Manning
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with mFOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)
Authors: A. Avallone, G. Nasti, G. Rosati, C. Carlomagno, C. Romano, D. Bilancia, A. De Stefano, A. Ottaiano, A. Cassata, L. Silvestro, S. Tafuto, F. Bianco, P. Delrio, F. Izzo, E. Di Gennaro, S. Lastoria, C. Gallo, F. Perrone, A. Budillon, M.C. Piccirillo
Journal: Annals of Oncology (2017)